We investigated whether FNIII14, a 22-mer peptide derived from fibronectin (FN) that potently impairs interaction of FN with b1-integrin, could overcome cell adhesion-mediated drug resistance (CAM-DR) induced by very late antigen (VLA)-4-to-FN interaction in acute myelogenous leukemia (AML). Two AML cell lines, U937 cells and HL-60 cells, and fresh leukemic cells from six AML patients with high a4-integrin expression exhibited CAM-DR to cytosine arabinoside (Ara C) through VLA-4-to-FN interaction, while fresh leukemic cells from two AML patients with low a4-integrin expression did not display CAM-DR to Ara C. FNIII14 impaired VLA-4-to-FN interaction and restored sensitivity to Ara C in the CAM-DR leukemic cells. In these CAM-DR leukemic cells, upregulation of Bcl-2, which was induced through the focal adhesion kinase/Akt signal pathway upon VLA-4-to-FN interaction, was inhibited by FNIII14 treatment. In a mouse model of minimal residual disease (MRD) in bone marrow, 100% survival was achieved by combining FNIII14 with Ara C, whereas Ara C alone prolonged survival only slightly. The myelosuppression induced by Ara C was not augmented by the combination of FNIII14 in mouse experiments. Thus, the combination of anticancer drugs and FNIII14 holds promise to eradicate MRD in bone marrow after chemotherapy.
Introduction
Acute myelogenous leukemia (AML) cells are generally chemosensitive, and 70-80% of AML patients undergo complete remission after chemotherapy. 1, 2 However, long-term diseasefree survival remains as low as 30-50%, [1] [2] [3] mainly because of relapse after chemotherapy. The relapse has been ascribed to minimal residual disease (MRD) in the bone marrow (BM). [4] [5] [6] We 4 showed that the interaction between very late antigen (VLA)-4 on leukemic cells and fibronectin (FN) on BM stromal cells induced drug resistance and could be a cause of MRD in BM. Further, we 4 and others 7 reported that levels of VLA-4 expression on leukemic cells negatively correlated with AML prognosis. The drug resistance induced by interaction of tumor cells with interstitial or the extracellular matrix (ECM) has been reported not only in AML, but also in other hematological malignancies [8] [9] [10] [11] and solid cancers [12] [13] [14] [15] [16] [17] and has been described as 'cell adhesion-mediated drug resistance' (CAM-DR).
To overcome the CAM-DR of AML, we 4 employed anti-VLA-4 (a4-integrin) monoclonal antibodies (VLA-4 Ab) in combination with an anticancer drug and successfully demonstrated eradication of bone marrow MRD in mice transplanted with human AML cells. This modality to eradicate MRD by blocking the VLA-4-to-FN interaction could be further fortified by alternative approaches targeting VLA-4.
FNIII14, 18 ,19 a 22-mer peptide derived from the 14th type III module of FN, has been shown to have a strong inhibitory effect on b1-integrin (VLA-4 and -5)-mediated adhesion to FN [19] [20] [21] [22] of tumor cells including the A375SM melanoma cell line, the K562 human erythroleukemic cell line and the Ramos human Burkitt's lymphoma cell line. 23 It was also shown that FNIII14 clearly prevented murine T-lymphoma cell metastasis. 21 Since peptide preparation is generally less expensive than humanizing antibody, it may be worthy to study FNIII14 in eradication of MRD in terms of cost/benefit for clinical use.
In this study, we investigated whether a combination therapy of FNIII14 and an anticancer drug could overcome CAM-DR of AML using an in vitro assay system and in vivo mouse models.
Materials and methods

Peptides and fibronectin
Synthetic peptide FNIII14, corresponding to residues 1835-1855 of FN, 19 and its analogous inactive scrambled control peptide FNIII14scr were obtained from Operon Biotechnologies (Tokyo, Japan).
Antibodies
Anti-a4-integrin monoclonal antibody (mAb) (SG/73), [24] [25] [26] [27] [28] [29] anti-a5-integrin mAb (KH/72) 24, 26, 29 and anti-b1-integrin mAb (SG/19) 25 were kindly provided by Prof. K Miyake.
Patients
Eight untreated de novo AML patients were enrolled in this study. They happened to be all male and their ages ranged from 42 to 81. French-American-British classifications and karyotypes are listed in Table 1 . 
Leukemic cells and culture conditions
FACS analyses
Expression of VLA-4 (a4b1-integrin) and VLA-5 (a5b1-integrin) molecules on U937 cells, HL-60 cells or leukemic cells from the patients was analyzed by fluorescence-activated cell sorting (FACS) after the cells were incubated with primary antibodies (SG/73, KH/72 or SG/19), FITC-conjugated secondary antibodies and finally with phycoerythrin-conjugated CD45 antibodies. 30 
Anticancer drug
Cytosine arabinoside (Ara C) was purchased from Kyowa Hakko (Tokyo, Japan).
Cytotoxic assay
Leukemic cells (3 Â 10 4 ) suspended in RPMI1640 containing 10% FCS with 1 mM MgCl 2 were seeded on 96-well plates coated with bovine serum albumin (BSA) (5 mg ml À1 ) or FN in the presence or absence of FNIII14 (100 mg ml À1 ), FNIII14scr (100 mg ml À1 ), antia4-integrin mAb (SG/73) or anti-a5-integrin mAb (KH/72) and kept at 37 1C for 2 h. The indicated concentrations of Ara C were then added to the wells, and cells were cultured for 24 h. After the incubation, the number of viable cells was evaluated based on the conventional 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using a Cell Counting Kit (Wako, Tokyo, Japan) according to the manufacturer's instructions.
BCL-2 oligonucleotides
Bcl-2 sense and antisense oligonucleotides were purchased from Biomol International, LP (Plymouth Meeting, PA, USA). 
Western blot analyses
Western blot analyses were carried out as described previously.
22 U937 cells (1 Â 10 6 ) were seeded onto six-well plates coated with BSA (5 mg ml
À1
) or FN and then incubated at 37 1C for 2 h with or without FNIII14 (100 mg ml À1 ) or FNIII14scr (100 mg ml À1 ) in the presence of MgCl 2 (1 mM). For analysis of focal adhesion kinase (FAK), cell lysates containing equal amounts of protein were analyzed for activation and expression of FAK using anti-phosphorylated FAK (Tyr397) and anti-FAK mAb (Cell Signaling Technology, Beverly, MA, USA), respectively. For analysis of Akt, cells were further incubated with or without Ara C (1 Â 10 À6 M) for 6 h. Cell lysates with equal amounts of protein were analyzed for activation and expression of Akt using anti-phosphorylated Akt (Ser473) and anti-Akt mAb (Cell Signaling Technology), respectively. For analysis of Bcl-2, U937 cells transfected with or without Bcl-2 oligonucleotides (2.0 mM) were incubated as described above. After a 2 h incubation at 37 1C, cells were further incubated in the presence or absence of Ara C (1 Â 10
After an 18 h incubation, cell lysates containing equal amounts of protein were analyzed for the expression of Bcl-2 and b-actin using specific antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Mice
CB-17/lcrCrj-scid/scid severe combined immunodeficiency (SCID) mice (6 weeks old) were purchased from Charles River Japan Laboratories (Yokohama, Japan). C57BL/6 Cr Slc mice (6 weeks old) were purchased from Japan SLC Incorporation (Hamamatsu, Japan). Animal experiments were done in accordance with institutional guidelines approved by the Animal Care Committee of Sapporo Medical University School of Medicine.
Protocol for combination therapy of FNIII14 and Ara C in mice transplanted with U937 cells SCID mice were irradiated at 4 Gy and were then administered 5 Â 10 6 U937 cells intravenously. On day 7 after transplantation, 1 mg of FNIII14 or FNIII14scr was injected intravenously 
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into the U937-transplanted mice and either Ara C (20 mg) or normal saline was injected intraperitoneally.
PCR for Alu and erythropoietin receptor
We used human Alu and mice erythropoietin receptor (EPO-R) primers as described in a previous report. 31,32 PCR bands were analyzed using NIH Image software (National Institutes of Health), and the results were expressed as the relative density of each PCR product after normalizing for the amount of DNA-loaded based upon the intensity of the EPO-R band.
Evaluation of myelotoxicity of the combination therapy of FNIII14 and Ara C The C57BL/6 Cr Slc mice were administered Ara C (20 mg intraperitoneally) and FNIII14 (1 mg intravenously). In the control mice, Ara C was administered but FNIII14 was not.After 12 h, another dose of Ara C was administered. Complete blood count (CBC) was measured every day.
Statistical analyses
SAS programs (SAS Institute) 33 were used for the statistical analyses throughout the experiments. Survival curves were calculated by the Kaplan-Meier method.
Results
Characteristics of patients and expression levels of VLA-4 and -5 on leukemic cells
Characteristics of patients and their leukemic cells are described in Table 1 . We analyzed VLA-4 (a4b1-integrin) and VLA-5 (a5b1-integrin) expression levels on U937 cells, HL-60 cells and fresh leukemic cells from eight AML patients using FACS. All of these cells showed appreciable expression of both VLA-4 and -5, but not any other b1-integrins (Table 1) . More than 99% of cells from both AML cell lines, U937 and HL-60 expressed a4-, a5-and b1-integrins. Fresh AML cells from eight patients showed various percentages of a4-, a5-and b1-integrins. For example, between 11.5 and 99.5% of leukemic cells expressed a4-integrin.
FNIII14 inhibited CAM-DR to Ara C in leukemic cells
We next investigated whether CAM-DR to Ara C was induced in leukemic cells incubated on FN-coated plates. Both U937 cells ( Figure 1Aa ) and HL-60 cells (Figure 1Ab ) incubated on an FNcoated plate showed higher viability than those on a BSA-coated plate, even without Ara C. Ara C increased viability difference at all concentrations examined (Figures 1Aa and b) . We examined whether the CAM-DR phenomenon observed in FN-adhered leukemic cells persisted after exposure to 10 À4 M Ara C for more than 24 h. While both U937 cells and HL-60 cells cultured on (Figures 1Ac and d) . The number of viable cells cultured on FNcoated plates was at its lowest at 48 h and began increasing at 72 h (Figures 1Ac and d) . We next examined whether FNIII14, FNIII14scr, anti-a4-integrin mAb (VLA-4 Ab) or anti-a5-integrin mAb (VLA-5 Ab) inhibited CAM-DR in the two leukemic cell lines using 10 À6 M Ara C, a concentration adopted in chemotherapy of AML patients. The difference in viability between Ara C-treated cells incubated with FN and those incubated with BSA was eliminated by treatment with FNIII14 or VLA-4 Ab (Figures 1Ba and b) . However, combining FNIII14 with VLA-4 Ab did not enhance the inhibition of CAM-DR observed with FNIII14 or VLA-4 Ab alone. On the other hand, neither FNIII14scr nor VLA-5 Ab had any effect on viability. These results indicate that CAM-DR of the two cell lines was induced by the VLA-4-to-FN interaction and that FNIII14 inhibited the CAM-DR to Ara C as effectively as VLA-4 Ab. 4 We also studied the chemosensitivity of fresh leukemic cells from patients using 10 À6 M Ara C. Since we could not obtain a sufficient number of leukemic cells from the patients, dose dependency of CAM-DR could not be evaluated. Fresh leukemic cells from six patients (patients 1, 2, 3, 4, 5 and 6) whose percentages and mean fluorescence intensity (MFI) of a4-integrin expression were higher than 39.8% and 13.8, respectively, displayed CAM-DR (Figures 2a-f) . On the other hand, patient 7 and patient 8, whose percentages and MFI of a4-integrin expression were lower than 26.5% and 8.8, 
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respectively, did not exhibit CAM-DR (Figures 2g and h) . These data were consistent with that of our previous report. 4 We also tested the effect of FNIII14, FNIII14scr, VLA-4 Ab or VLA-5 Ab on CAM-DR of fresh leukemic cells. In leukemic cells from all six patients that showed CAM-DR, the difference in viability between Ara C-treated cells incubated with FN and those incubated with BSA was eliminated by treatment with FNIII14 or VLA-4 Ab (Figures 2a-f) . However, combining FNIII14 with VLA-4 Ab did not enhance the inhibition of CAM-DR observed upon treatment with FNIII14 or VLA-4 Ab alone.
On the other hand, neither VLA-5 Ab nor FNIII14scr had any effect on viability. However, the combination of FNIII14 and VLA-5 Ab showed a similar inhibitory effect on CAM-DR as FNIII14 alone. Thus, it was revealed that CAM-DR of leukemic cells from the patients was induced by the VLA-4-to-FN interaction and that FNIII14 inhibited CAM-DR to Ara C.
FNIII14 suppressed the expression of Bcl-2 induced by the VLA-4-to-FN interaction in U937 cells
We examined the phosphorylation status of FAK (Figure 3a) since it is reportedly induced by the VLA-4-to-FN interaction. 34, 35 We also examined the phosphorylation status of Akt (Figure 3b ) and the expression of Bcl-2 ( Figure 3c ) because we previously found that expression of Bcl-2, which is a well-accepted antiapoptotic factor against cytotoxic drugs, is enhanced upon interaction of VLA-4 with FN in leukemic cells and the subsequent activation of Akt (phosphorylation of Akt). 4 U937 cells incubated on the FN substrate showed incremental increases in phosphorylation of FAK and Akt and in expression of Bcl-2, as compared with those incubated on the BSA substrate. Phosphorylation of FAK was almost completely suppressed after culturing the cells in the presence of FNIII14. FNIII14scr showed no effect on FAK phosphorylation/activation. U937 cells incubated with Ara C on the FN substrate showed substantial suppression of phosphorylated Akt and Bcl-2 expression. Treatment of the cells with FNIII14 showed even greater suppression of phosphorylated Akt and of Bcl-2 expression compared to treatment with Ara C alone. When the cells were treated with a combination of Ara C and FNIII14, almost complete suppression of phosphorylated Akt and Bcl-2 was observed. FNIII14scr did not show any effect on Akt phosphorylation or Bcl-2 expression in U937 cells. Treatment of the cells with a combination of Ara C and FNIII14scr showed similar suppression of phosphorylated Akt and of Bcl-2 expression compared to treatment with Ara C alone (data not shown). To determine whether increased Bcl-2 is relevant to resistance acquisition, we treated the cells with antisense BCL-2 oligonucleotides. Antisense oligonucleotides alone suppressed Bcl-2 expression, even more so when combined with Ara C, and restored chemosensitivity (Figures 3d and e) . 
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Combined administration of FNIII14 peptide and Ara C abrogated MRD in U937-inoculated mice
In a previous study, 4 we established MRD in BM of SCID mice at day 7 (day 7 mice) after administration of U937 cells through the tail vein. In the present experiment, we confirmed this previous observation by detecting the human-specific Alu sequence by PCR in BM of day 7 mice (Figure 4Aa ). Using these model mice, we examined the effect of combined treatment with FNIII14 and Ara C on MRD. As shown in Figure 4b , the mean survivals of the mice receiving vehicle, FNIII14 or FNIII14scr were 25, 26 and 24 days, respectively (control group). Treatment with vehicle plus Ara C and FNIII14scr plus Ara C significantly prolonged the survival of mice compared to those of the control group. In these mice, various organs were positive for Alu bands on day 34 (Figure 4Ab) . The mice treated with FNIII14 and Ara C all survived until the end of the observation period (62 days), and the BM from mice that survived until day 62 was Alu negative (Figure 4Ac ).
Combined treatment of FNIII14 peptide and Ara C did not augment the myelosuppression observed with Ara C treatment
We finally examined whether FNIII14 enhances the myelosuppression observed with anticancer drugs. We administered Ara C alone or Ara C plus FNIII14 to C57BL/6 Cr Slc mice on day 0 and monitored their CBC every day for 11 days. The curves of white blood cells, neutrophils, lymphocytes and platelets of the mice injected with Ara C alone and the mice injected with Ara C plus FNIII14 showed quite similar patterns; suppression of these four types of blood cells was similarly transient (days 1-6) and the degrees of trough were similar in both groups (data not shown). The results indicate that FNIII14 did not enhance the myelosuppression of Ara C.
Discussion
In this study, we first demonstrated that the FNIII14 peptide efficiently overcame CAM-DR of established AML cell lines and of fresh AML cells from patients in vitro using FN plates. Since we previously determined that the FNIII14 peptide is a potent inhibitor of b1-integrins, regardless of the associated asubunit, [19] [20] [21] [22] the restoration of chemosensitivity by this peptide could be ascribed to blocking either or both the a4b1-integrin (VLA-4)-to-FN interaction and the a5b1-integrin (VLA-5)-to-FN interaction. We demonstrated that FNIII14 alone and in combination with VLA-4 Ab restored chemosensitivity. However, while VLA-5 Ab alone did not inhibit CAM-DR, combination with FNIII14 restored chemosensitivity (Figures 1Ba and b) , clearly indicating that FNIII14 acted on VLA-4 of AML cells and not VLA-5. We then explored the effect of FNIII14 on the signals that induce chemoresistance and found that FAK/AKT/Bcl-2 signal pathway was inhibited by the peptide in a manner similar to VLA-4 Ab. 4 These observations suggest that the mechanism by which FNIII14 acts on AML cells in vitro is essentially the same as that of VLA-4 Ab. In addition to the FAK/AKT/Bcl-2 signaling pathway of AML cells, there are many other signaling pathways that induce antiapoptotic activity or growth promotion through the adhesion of cells to ECM components. 12, [36] [37] [38] [39] [40] [41] Therefore we surmised that the mechanism for anoikis resistance almost certainly differs between cell types.
We next demonstrated that treatment of AML with a combination of FNIII14 and an anticancer drug successfully Fibronectin peptide inhibits CAM-DR of AML T Matsunaga et al eradicated the MRD in BM, resulting in a 100% survival rate during the observation period. Thus, our previous results using VLA-4 Ab 4 were bolstered by the in vitro and in vivo experimental results obtained using FNIII14.
We next tackled the issue of the adverse effect of this modality on normal hematopoiesis, which was not addressed in the previous study using VLA-4 Ab. 4 Although b1-integrin is highly expressed on hematopoietic stem cells, we observed no enhancement of myelosuppression by FNIII14 plus Ara C when compared to that of Ara C alone (data not shown). This indicates that this modality generates an amount of toxicity acceptable for normal hematopoiesis. Though speculative, the reason why the myelosuppression of Ara C was not enhanced by FNIII14 may be related to the fact that hematopoietic stem cells are generally resistant to anticancer drugs including Ara C because the majority of stem cells are dormant in cell cycle 42, 43 and are equipped with a multidrug-resistant apparatus. 44 In organs other than BM, b1-integrin may also be playing some crucial physiological roles. However, FNIII14 may be administered only for an induction therapy period and may not be chronically used, causing the interaction between b1-integrin and its receptor to be transiently blocked by FNIII14. Therefore, FNIII14 application may not cause severe adverse effects in these organs as well. An additional advantage of FNIII14 over VLA-4 Ab is that the peptide preparation is generally less expensive than humanized antibody preparation, and it is practical for clinical use considering the cost/benefit ratio. Furthermore, FNIII14 may also be effective for treating those malignancies in which CAM-DR is mediated by b1-integrins other than VLA-4, such as VLA-5. 45, 16 On the other hand, the plausible disadvantage of peptide preparation is its relatively shorter half-life in circulation 46 than protein preparations. 47 However, this problem may be conquered by modification of the peptide with polyethyleneglycol conjugation, 48 protease modification 49 or hydrocarbon stapling. 50 Furthermore, with regard to the effects of FNIII14, our extensive investigations into a broad range of malignant cells have so far revealed consistent results, 51 suggesting that FNIII14 may have wide practical applicability.
In conclusion, the combination treatment of anticancer drugs plus the peptide FNIII14 may be promising to improve the prognosis for AML patients.
